RESUMO
This study aimed to examine the effects of diallyl trisulfide (DATS), the most potent polysulfide derived from garlic, on metabolic syndrome and myocardial function in rats with metabolic syndrome (MetS). For that purpose, we used 36 male Wistar albino rats divided into control rats, rats with MetS and MetS rats treated with 40 mg/kg of DATS every second day for 3 weeks. In the first part, we studied the impact of DATS on MetS control and found that DATS significantly raised H2S, decreased homocysteine and glucose levels and enhanced lipid and antioxidative, while reducing prooxidative parameters. Additionally, this polysulfide improved cardiac function. In the second part, we investigated the impact of DATS on ex vivo induced ischemia/reperfusion (I/R) heart injury and found that DATS consumption significantly improved cardiodynamic parameters and prevented oxidative and histo-architectural variation in the heart. In addition, DATS significantly increased relative gene expression of eNOS, SOD-1 and -2, Bcl-2 and decreased relative gene expression of NF-κB, IL-17A, Bax, and caspases-3 and -9. Taken together, the data show that DATS can effectively mitigate MetS and have protective effects against ex vivo induced myocardial I/R injury in MetS rat.
Assuntos
Compostos Alílicos/uso terapêutico , Cardiotônicos/uso terapêutico , Alho/química , Síndrome Metabólica/tratamento farmacológico , Sulfetos/uso terapêutico , Compostos Alílicos/farmacologia , Animais , Glicemia/metabolismo , Cardiotônicos/farmacologia , Regulação da Expressão Gênica/efeitos dos fármacos , Teste de Tolerância a Glucose , Testes de Função Cardíaca/efeitos dos fármacos , Insulina/sangue , Linfonodos/efeitos dos fármacos , Linfonodos/patologia , Síndrome Metabólica/sangue , Síndrome Metabólica/fisiopatologia , Miocárdio/patologia , Oxirredução , Estresse Oxidativo/efeitos dos fármacos , Ratos Wistar , Sulfetos/farmacologiaRESUMO
In view of the emerging COVID19 pandemic caused by SARSCoV2 virus, the search for potential protective and therapeutic antiviral strategies is of particular and urgent interest. Zinc is known to modulate antiviral and antibacterial immunity and regulate inflammatory response. Despite the lack of clinical data, certain indications suggest that modulation of zinc status may be beneficial in COVID19. In vitro experiments demonstrate that Zn2+ possesses antiviral activity through inhibition of SARSCoV RNA polymerase. This effect may underlie therapeutic efficiency of chloroquine known to act as zinc ionophore. Indirect evidence also indicates that Zn2+ may decrease the activity of angiotensinconverting enzyme 2 (ACE2), known to be the receptor for SARSCoV2. Improved antiviral immunity by zinc may also occur through upregulation of interferon α production and increasing its antiviral activity. Zinc possesses antiinflammatory activity by inhibiting NFκB signaling and modulation of regulatory Tcell functions that may limit the cytokine storm in COVID19. Improved Zn status may also reduce the risk of bacterial coinfection by improving mucociliary clearance and barrier function of the respiratory epithelium, as well as direct antibacterial effects against S. pneumoniae. Zinc status is also tightly associated with risk factors for severe COVID19 including ageing, immune deficiency, obesity, diabetes, and atherosclerosis, since these are known risk groups for zinc deficiency. Therefore, Zn may possess protective effect as preventive and adjuvant therapy of COVID19 through reducing inflammation, improvement of mucociliary clearance, prevention of ventilatorinduced lung injury, modulation of antiviral and antibacterial immunity. However, further clinical and experimental studies are required.